NCT04198623View on ClinicalTrials.gov

Efficacy of Montelukast in Reducing the Incidence and Severity of Monoclonal Antibodies Associated Infusion Reactions

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 20, 2020

Primary Completion Date

July 31, 2024

Study Completion Date

July 31, 2024

Conditions

Infusion ReactionMonoclonal Antibody

Interventions

DRUG

Montelukast 10 Mg Oral Tablet

Montelukast(Singulair) 10mg to be taken at least 2 hours prior to initiation of monoclonal antibody infusion addition to institutional protocol premedication regiment

Trial Locations (1)

93611

Community Cancer Institute, Clovis

All Listed Sponsors

lead

University of California, San Francisco

OTHER

NCT04198623 - Efficacy of Montelukast in Reducing the Incidence and Severity of Monoclonal Antibodies Associated Infusion Reactions | Biotech Hunter | Biotech Hunter